Kathleen Halka is a Hematology physician affiliated with Baylor Scott & White Health. OpenAlex indexes 15 publications with 1,551 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2401 S 31st St
Temple, TX 76508
Telephone
254-724-2111Provider last certified this registry record 7 Dec 2021.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Agios Pharmaceuticals, Inc.Program year20242 payments
- Janssen Biotech, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
100%Vitamin K antagonist78.3%Warfarin Sodium84%Jantoven16%Part D≥477 patientsFactor Xa inhibitor17.8%Eliquis52%Xarelto40%Fondaparinux Sodium9%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B
New England Journal of Medicine
2025 - A Case of Acquired Hemophilia A in a Patient with Exposure to COVID-19
Case Reports in Hematology
2022 - A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.
Journal of Clinical Oncology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Karen Fink, PhD, MD
Baylor Scott & White Health
Garry Schwartz, MD
Baylor Scott & White Health
Robert Hebeler, MD
Baylor Scott & White Health
Harry Papaconstantinou, MD
Baylor Scott & White Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”